Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

HeartWare Presentation At The 25th Annual Piper Jaffray Healthcare Conference To Be Webcast



HeartWare Presentation At The 25th Annual Piper Jaffray Healthcare Conference
                                To Be Webcast

PR Newswire

FRAMINGHAM, Mass., Nov. 25, 2013

FRAMINGHAM, Mass., Nov. 25, 2013 /PRNewswire/ -- HeartWare International, Inc.
(NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory
support technologies that are revolutionizing the treatment of advanced heart
failure, today announced that CEO Doug Godshall is scheduled to present at the
25th Annual Piper Jaffray Healthcare Conference at 2:00 p.m. ET on Tuesday,
December 3, 2013.  The conference is being held December 3-4 at the Palace
Hotel in New York City.

A live webcast of the Company's presentation at the conference will be
available via a link provided at www.heartware.com.  A replay of the webcast
will be available for 90 days at the site after the presentation.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable
heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The HeartWare^® Ventricular Assist
System features the HVAD^® pump, a small full-support circulatory assist
device designed to be implanted next to the heart, avoiding the abdominal
surgery generally required to implant competing devices. The HeartWare System
is approved in the United States for the intended use as a bridge to cardiac
transplantation in patients who are at risk of death from refractory end-stage
left ventricular heart failure, has received CE Marking in the European Union
and has been used to treat patients in 36 international countries. The device
is also currently the subject of a U.S. clinical trial for destination
therapy. For additional information, please visit the Company's website at
www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000^® and its
securities are publicly traded on The NASDAQ Stock Market.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of
HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.

Website: http://www.heartware.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement